Literature DB >> 28127708

Associations between Hunter Type A/B Personality and Cardiovascular Risk Factors from Adolescence through Young Adulthood.

Benjamin D Pollock1, Wei Chen2, Emily W Harville2, Lydia A Bazzano2.   

Abstract

PURPOSE: Type A personality, characterized by action-oriented tendencies, has been linked to cardiovascular disease in middle-aged and elderly adults. Alternatively, limited research has tested whether personality type A/B and cardiovascular (CVD) risk are linked prior to adulthood. Therefore, we used the Hunter-Wolf A/B personality score to determine whether personality type A/B is associated with traditional CVD risk factors during adolescence, and more importantly if personality type, or its individual type A components, are associated with cardiovascular risk through young adulthood. This study is the first to assess personality type A/B on a continuous spectrum with regard to its relationship with cardiovascular disease risk, as well as the first to examine this association in a biracial, adolescent population.
METHODS: Subjects (3396) from the Bogalusa Heart Study were surveyed from 1984 to 1986, and multivariable regression was used to test adjusted, cross-sectional associations between personality type A/B, as determined by Hunter-Wolf A/B personality questionnaire, and CVD risk factors during adolescence. To test whether associations existed longitudinally, subjects were followed through 2007, and general estimating equation (GEE) models were used to examine the associations of personality type A/B with CVD risk factors, as well as with Framingham risk score as a global score of CVD risk. The component traits of type A personality (leadership, hard-driving, eagerness-energy, and impatience-aggression) were tested individually to determine their independent, longitudinal associations with global CVD risk.
RESULTS: Baseline mean (SD) age was 15.9(5.2). Mean( SD) Hunter-Wolf score in was 96.9 (11.6). After adjustment, more type A Hunter-Wolf scores were cross-sectionally associated with lower alcohol consumption (p = 0.03), female gender (p < 0.0001), and black race (p < 0.0001) in adolescence. After follow-up (median = 11 years), personality type A/B as the continuous Hunter-Wolf score was non-linearly associated with young adult BMI (p = 0.01), fasting blood glucose (p < 0.01), and Framingham score (p = 0.05). Of the type A components, leadership and hard-driving were non-linearly associated with Framingham risk at follow-up (both p < 0.0001).
CONCLUSIONS: Adolescent personality type A is associated with female gender and black race. Generally, type A children have higher CVD risk during young adulthood, though this relationship is non-linear. Additionally, adolescents exhibiting strong leadership-oriented personality traits have worse cardiovascular risk profiles in early adulthood, whereas hard-driving adolescent personalities are protective of young adult CVD risk. Our results warrant consideration of personality as a continuous, non-categorical, trait in studies of cardiovascular disease.

Entities:  

Keywords:  Cardiovascular risk; Childhood; Personality type; Young adult

Mesh:

Year:  2017        PMID: 28127708      PMCID: PMC6791370          DOI: 10.1007/s12529-017-9636-5

Source DB:  PubMed          Journal:  Int J Behav Med        ISSN: 1070-5503


  45 in total

1.  Association of specific overt behavior pattern with blood and cardiovascular findings; blood cholesterol level, blood clotting time, incidence of arcus senilis, and clinical coronary artery disease.

Authors:  M FRIEDMAN; R H ROSENMAN
Journal:  J Am Med Assoc       Date:  1959-03-21

2.  Changes in the serum cholesterol and blood clotting time in men subjected to cyclic variation of occupational stress.

Authors:  M FRIDEMAN; R H ROSENMAN; V CARROLL
Journal:  Circulation       Date:  1958-05       Impact factor: 29.690

Review 3.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

4.  Assessment of type A behavior in children: a comparison of two instruments.

Authors:  E G Bishop; B J Hailey; H N Anderson
Journal:  J Human Stress       Date:  1987

5.  Comparison of the Matthews Youth Test for Health and the Hunter-Wolf A-B Rating Scale: measures of type A behavior in children.

Authors:  C Jackson; D W Levine
Journal:  Health Psychol       Date:  1987       Impact factor: 4.267

6.  Clustering of risk habits in young adults. The Cardiovascular Risk in Young Finns Study.

Authors:  O T Raitakari; M Leino; K Räkkönen; K V Porkka; S Taimela; L Räsänen; J S Viikari
Journal:  Am J Epidemiol       Date:  1995-07-01       Impact factor: 4.897

7.  Validation of a measure of type A behavior pattern in children: Bogalusa heart study.

Authors:  T M Wolf; M C Sklov; P A Wenzl; S M Hunter; G S Berenson
Journal:  Child Dev       Date:  1982-02

8.  Anger expression and risk of coronary heart disease: evidence from the Nova Scotia Health Survey.

Authors:  Karina W Davidson; Elizabeth Mostofsky
Journal:  Am Heart J       Date:  2010-02       Impact factor: 4.749

9.  Type A eagerness-energy across developmental periods predicts adulthood carotid intima-media thickness: the Cardiovascular Risk in Young Finns Study.

Authors:  Liisa Keltikangas-Järvinen; Taina Hintsa; Mika Kivimäki; Sampsa Puttonen; Markus Juonala; Jorma S A Viikari; Olli T Raitakari
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-10       Impact factor: 8.311

10.  Type A behavior pattern is not a predictor of premature mortality.

Authors:  Kastytis Šmigelskas; Nida Žemaitienė; Juhani Julkunen; Jussi Kauhanen
Journal:  Int J Behav Med       Date:  2015-04
View more
  1 in total

1.  Response to comments on: Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy.

Authors:  Ender Sirakaya; Zeynep Duru; Bekir Kuçuk; Necati Duru
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.